03/01/2025
🌍 Beyond Rare. Beyond Imagination.
On Rare Disease Day 2025, Pulnovo Medical stands with the global rare disease community — not only to raise awareness, but to illuminate a new frontier in Pulmonary Hypertension treatment.
Every breakthrough begins with a boundary.
Every boundary is an opportunity for redefinition.
PADN — Pulmonary Artery Denervation
The world’s first-in-class interventional therapy for pulmonary hypertension,now advancing globally with FDA Breakthrough Device Designation,covering Group I, Group II, and Group IV pulmonary hypertension.In late 2023, PADN received both NMPA approval and FDA HUD designation,marking a critical step from original innovation to global adoption.
🌍 PADN — More Than You Can Imagine.
